Surging US demand triggers new $2.9B purchase of Regeneron's Covid-19 antibodies

Amber Tong

Regeneron has received a new $2.9 billion order for its Covid-19 antibody cocktail as demand for monoclonal antibodies surges in the US amid a spike …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Surging US demand triggers new $2.9B purchase of Regeneron's Covid-19 antibodies

Amber Tong

Sign up to read this article for free.

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Acadia snaps up an essential tremor drug after field's summer setbacks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Surg­ing US de­mand trig­gers new $2.9B pur­chase of Re­gen­eron's Covid-19 an­ti­bod­ies

Amber Tong

Sign up to read this article for free.

more like this

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Surging US demand triggers new $2.9B purchase of Regeneron's Covid-19 antibodies

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Acadia snaps up an essential tremor drug after field's summer setbacks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks